Estados financieros detallados de Damora Therapeutics, Inc. (GLTO): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $21.58, GLTO presenta beneficios negativos (P/E no significativo) y un ROE del -82.56%. La capitalización bursátil es de $34M.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | $111000 | 0 | 0 | 0 | 0 | 0 | $34000 |
| Beneficio Bruto | 0 | -$111000 | 0 | 0 | 0 | 0 | 0 | -$34000 |
| I+D | $10.1M | $36.5M | $24.6M | $38.5M | $48.2M | $23.8M | $10.8M | $201.2M |
| Generales y Administrativos | $2.8M | $2.4M | $9.0M | $13.7M | $13.0M | $12.7M | $10.5M | $9.7M |
| Gastos Operativos | $12.9M | $39.0M | $33.6M | $52.2M | $61.2M | $39.9M | $22.3M | $210.9M |
| Beneficio Operativo | -$12.9M | -$39.0M | -$33.6M | -$52.2M | -$61.2M | -$39.9M | -$22.3M | -$210.9M |
| EBITDA | -$12.9M | -$36.4M | -$34.6M | -$51.3M | -$60.7M | -$35.6M | -$21.1M | -$209.8M |
| Gastos por Intereses | $3.0M | 0 | 0 | 0 | $417000 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$15.9M | -$36.5M | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$209.8M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | $41000 | $50000 |
| Beneficio Neto | -$15.9M | -$38.4M | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$209.8M |
| BPA | $-4.42 | $-37.76 | $-35.66 | $-50.75 | $-61.04 | $-36.08 | $-18.53 | $-152.99 |
| BPA Diluido | $-4.42 | $-37.76 | $-35.66 | $-50.75 | $-61.04 | $-36.08 | $-18.53 | $-152.99 |
| Acciones en Circulación (Diluidas) | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.1M | $1.2M | $1.4M |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $31.0M | $11.3M | $163.6M | $62.6M | $32.8M | $21.5M | $14.2M | $257.6M |
| Inversiones a Corto | 0 | 0 | 0 | $37.6M | $27.4M | $11.7M | 0 | 0 |
| Cuentas por Cobrar | $989000 | $41.1M | $2.2M | $2.3M | $1.4M | $1.7M | $881000 | $899000 |
| Inventario | $3.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $35.0M | $56.1M | $169.3M | $110.1M | $63.9M | $36.8M | $16.8M | $260.4M |
| Inmovilizado Material | 0 | $298000 | $885000 | $1.0M | $1.2M | $325000 | $130000 | $104000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $35.1M | $56.6M | $171.6M | $122.2M | $73.2M | $38.2M | $17.1M | $260.5M |
| Cuentas por Pagar | $1.4M | $3.3M | $2.9M | $1.5M | $3.4M | $1.7M | $377000 | $444000 |
| Deuda a Corto | 0 | $87000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $4.4M | $7.9M | $5.6M | $4.5M | $11.1M | $5.8M | $1.2M | $20.1M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $4.4M | $8.1M | $6.1M | $5.0M | $11.4M | $5.9M | $1.3M | $20.1M |
| Reservas | -$33.0M | -$69.5M | -$104.4M | -$156.1M | -$217.7M | -$256.1M | -$277.5M | -$487.4M |
| Patrimonio Neto | $30.7M | $48.5M | $165.5M | $117.2M | $61.8M | $32.3M | $15.8M | $240.4M |
| Deuda Total | 0 | $298000 | $915000 | $847000 | $804000 | $249000 | $73000 | $68000 |
| Deuda Neta | -$31.0M | -$11.0M | -$162.7M | -$99.3M | -$59.4M | -$32.9M | -$14.1M | -$257.6M |
| Capital Circulante | $30.5M | $48.2M | $163.7M | $105.6M | $52.8M | $30.9M | $15.6M | $240.4M |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$15.9M | -$36.5M | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$209.8M |
| Amortizaciones | 0 | $111000 | $188000 | $441000 | $490000 | $830000 | $181000 | $34000 |
| Compensación en Acciones | $81000 | 0 | $982000 | $4.5M | $5.6M | $5.4M | $3.2M | $998000 |
| Cambio en Capital Circulante | -$933000 | $2.2M | -$4.6M | -$6.6M | $11.9M | -$4.4M | -$2.7M | $18.4M |
| Flujo de Caja Operativo | -$13.7M | -$19.3M | -$38.2M | -$52.3M | -$42.9M | -$36.9M | -$18.6M | -$6.7M |
| Inversiones (CapEx) | 0 | 0 | 0 | -$223000 | -$196000 | 0 | 0 | 0 |
| Adquisiciones | 0 | -$326000 | 0 | $47825 | $70000 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$13.7M | -$19.3M | -$38.2M | -$52.5M | -$43.1M | -$36.9M | -$18.6M | -$6.7M |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -142.1% | +9.3% | -48.6% | -19.1% | +37.8% | +44.1% | -878.8% | |
| Crecimiento BPA (anual) | -754.3% | +5.6% | -42.3% | -20.3% | +40.9% | +48.6% | -725.6% | |
| Cambio en Acciones (anual) | +0.0% | -0.7% | +0.0% | +0.6% | +4.6% | +8.9% | +18.5% | |
| Crecimiento FCF (anual) | -41.2% | -97.7% | -37.5% | +17.9% | +14.4% | +49.5% | +63.9% | |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.2% | -0.0% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-13.46 | $-19.00 | $-37.81 | $-51.99 | $-42.43 | $-34.73 | $-16.09 | $-4.90 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.1M | $1.2M | $1.4M |
Qué mirar en Salud / Farma
El pipeline de I+D es el activo invisible. Patentes que caducan = ingresos que evaporan. Mira innovación y flujo de caja.
- I+D / Ingresos — Indica inversión en pipeline futuro. Farma seria reinvierte 15-20%
- Crecimiento EPS 5y — Tras caducidad de patentes, ¿siguen creciendo?
- Margen bruto — Farma de marca >70%. Genéricos mucho más bajo — define el tipo de negocio
- FCF / Net Income — Calidad del beneficio — farma grande debería convertir >90%
- ROIC — Capital reinvertido con eficiencia — clave en farma por ciclos de I+D largos
- Deuda neta / EBITDA — Adquisiciones de farma generan mucha deuda — ojo al post-M&A
- P/E vs historial 10y propio — La mejor comparación es con su propia historia, no con competidores
Rentabilidad
| Rentabilidad sobre capital | -82.56% |
| Rentabilidad sobre capital invertido | -52.44% |
| Rentabilidad sobre activos | -48.35% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 19.73 |
Ratios Clave (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -84.84 | -9.93 | -8.77 | -1.49 | -0.47 | -0.50 | -0.25 | -0.15 |
| P/VC | 12.44 | 7.87 | 1.91 | 0.65 | 0.47 | 0.59 | 0.34 | 0.13 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: ACXP · ADIL · APRE · APVO · BCDA · INAB · KPRX
Explorar sector: Healthcare · Medical - Pharmaceuticals
Más secciones de GLTO: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones